These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Regulation of the expression of multiple class II genes in murine B cells by B cell stimulatory factor-1 (BSF-1).
    Author: Noelle RJ, Kuziel WA, Maliszewski CR, McAdams E, Vitetta ES, Tucker PW.
    Journal: J Immunol; 1986 Sep 01; 137(5):1718-23. PubMed ID: 3489040.
    Abstract:
    We have studied the mechanisms governing the induction of class II major histocompatibility complex (MHC) antigens on murine B lymphocytes by B cell stimulatory factor-1 (BSF-1). BSF-1 induced a dramatic (10- to 15-fold) and selective increase in class II MHC antigen expression, as judged by flow cytometry. Analysis of radiolabeled membrane proteins on BSF-1-induced B cells also showed that the expression of class II MHC antigens was increased 10- to 15-fold. Biosynthetic labeling studies established that a selective increase in the translation of class II MHC molecules could be detected at 5 to 6 hr post-addition of BSF-1 to culture. After 16 hr of culture, when cell surface expression was induced 12- to 15-fold, biosynthesis rates of class II MHC antigens was induced fivefold to sixfold. The biosynthesis of the I region-associated invariant chain (Ii) was also enhanced. Actinomycin D abrogated the increased biosynthetic labeling of class II products, suggesting transcriptional regulation of expression. At 6 hr after addition of BSF-1, there was a twofold increase in the steady-stage level of class II mRNA, which was slightly increased at 16 hr. The BSF-1-induced increase in surface Ia antigen is dependent on new transcription and translation. However, posttranslational events that lead to a decrease in membrane antigen turnover rate or to an increase in protein stability probably also play a significant role in the hyperexpression of class II antigens on BSF-1-treated B lymphocytes.
    [Abstract] [Full Text] [Related] [New Search]